CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 60 target
Drug / intervention
Nextida GC-B +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07149064
NCT07149064N/ARecruitingOn TrackUpdated 3mo ago
CompareCT.gov

A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes

Rousselot BVBA·interventional·Posted Aug 29, 2025·Updated Mar 16, 2026

In Brief

A clinical study evaluating Nextida GC-B and Placebo for Normoglycemia and 2 related conditions. Currently recruiting, targeting 60 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is: What is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormoglycemia, Prediabetes, Glycemic Control
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

N/ARecruiting
2026
First PostedAug 29, 2025
Enrollment StartFeb 18, 2026
Primary CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 5 monthsPosted 10 months agoPrimary completion in 1 month

Interventions

Nextida GC-Bdietary

One liquid shot contains 5 g of collagen hydrolysate.

Placeboother

One liquid shot contains non-active ingredients in Nextida GC-B (water, Erythritol, Citric Acid, DL-Malic Acid, Natural Apples Flavor, Steviol Glycosides).